Novel immunotherapies and combinations: the future landscape of multiple myeloma treatment
S Morè, L Corvatta, VM Manieri, E Morsia, A Poloni… - Pharmaceuticals, 2023 - mdpi.com
In multiple myeloma impressive outcomes have improved with the introduction of new
therapeutic approaches, mainly those including naked monoclonal antibodies such as …
therapeutic approaches, mainly those including naked monoclonal antibodies such as …
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
The objective of our study was to report real-world data on the safety and efficacy of
standard-of-care teclistamab in patients with relapsed/refractory multiple myeloma (MM) …
standard-of-care teclistamab in patients with relapsed/refractory multiple myeloma (MM) …
Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials
X Wang, A Zhao, J Zhu, T Niu - Frontiers in Immunology, 2024 - frontiersin.org
Objective Bispecific antibody (BsAbs) therapy represents a promising immunotherapeutic
approach with manageable toxicity and noteworthy preliminary efficacy in treating patients …
approach with manageable toxicity and noteworthy preliminary efficacy in treating patients …
Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
Bispecific antibodies (bsAbs) targeting B-cell maturation antigen (BCMA) have transformed
the landscape of relapsed/refractory (R/R) multiple myeloma, with single-agent response …
the landscape of relapsed/refractory (R/R) multiple myeloma, with single-agent response …
Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study
B-cell maturation antigen (BCMA)-directed T cell therapies such as idecabtagene vicleucel
(ide-cel), ciltacabtagene autoleucel (cilta-cel), teclistamab, and elranatamab have changed …
(ide-cel), ciltacabtagene autoleucel (cilta-cel), teclistamab, and elranatamab have changed …
[HTML][HTML] Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study
A Jourdes, E Cellerin, C Touzeau, S Harel… - Clinical Microbiology …, 2024 - Elsevier
Abstract Objectives Bispecific antibodies (BsAbs) are an effective treatment used in relapsed
or refractory multiple myeloma. Despite a well-tolerated safety profile, infectious events …
or refractory multiple myeloma. Despite a well-tolerated safety profile, infectious events …
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
K Nath, T Shekarkhand, D Nemirovsky… - Blood Cancer …, 2024 - nature.com
Abstract B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple
myeloma, but infections are emerging as a major challenge. In this retrospective, single …
myeloma, but infections are emerging as a major challenge. In this retrospective, single …
[PDF][PDF] Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma
Author contributions and disclosures: HL and IS designed the project and IS digitized the
data of the MajesTec-1 study and created the figures. All authors (NM, ET, NR, PM, AN, HL …
data of the MajesTec-1 study and created the figures. All authors (NM, ET, NR, PM, AN, HL …
Charting the Course: Sequencing Immunotherapy for Multiple Myeloma
Multiple chimeric antigen receptor (CAR) T-cell and bispecific antibody (bsAb) therapies
have been approved, demonstrating impressive clinical efficacy in relapsed/refractory …
have been approved, demonstrating impressive clinical efficacy in relapsed/refractory …
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
R Chakraborty, H Cheruvalath, A Patwari… - Blood Cancer …, 2024 - nature.com
Bispecific antibodies [bsAb] targeting B-cell maturation antigen [BCMA] and G-protein-
coupled receptor class C group 5 member D [GPRC5D] have demonstrated deep and …
coupled receptor class C group 5 member D [GPRC5D] have demonstrated deep and …